BR112016030577A2 - vacinas contra o vírus da gripe e usos das mesmas - Google Patents

vacinas contra o vírus da gripe e usos das mesmas

Info

Publication number
BR112016030577A2
BR112016030577A2 BR112016030577A BR112016030577A BR112016030577A2 BR 112016030577 A2 BR112016030577 A2 BR 112016030577A2 BR 112016030577 A BR112016030577 A BR 112016030577A BR 112016030577 A BR112016030577 A BR 112016030577A BR 112016030577 A2 BR112016030577 A2 BR 112016030577A2
Authority
BR
Brazil
Prior art keywords
influenza vaccines
methods
same
stem domain
domain polypeptides
Prior art date
Application number
BR112016030577A
Other languages
English (en)
Other versions
BR112016030577A8 (pt
Inventor
Impagliazzo Antonietta
Wilem Meijberg Jan
Radosevic Katarina
Wagner Michelle
Ding Zhaoqing
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016030577(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of BR112016030577A2 publication Critical patent/BR112016030577A2/pt
Publication of BR112016030577A8 publication Critical patent/BR112016030577A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

são fornecidos aqui polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, métodos para proporcionar poli-peptídeos do domínio de haste da hemaglutinina, composições compreendendo os mesmos, vacinas compreendendo os mesmos e métodos de seu uso, em particular na detecção, prevenção e/ou tratamento da gripe.
BR112016030577A 2014-07-10 2015-07-09 polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes BR112016030577A8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14176459 2014-07-10
US201462062754P 2014-10-10 2014-10-10
EP14195143 2014-11-27
EP15155761 2015-02-19
PCT/EP2015/065663 WO2016005482A1 (en) 2014-07-10 2015-07-09 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
BR112016030577A2 true BR112016030577A2 (pt) 2017-10-31
BR112016030577A8 BR112016030577A8 (pt) 2021-07-20

Family

ID=55063616

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030577A BR112016030577A8 (pt) 2014-07-10 2015-07-09 polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes

Country Status (17)

Country Link
US (1) US10117925B2 (pt)
EP (1) EP3166963B1 (pt)
JP (1) JP7094103B2 (pt)
KR (1) KR102463632B1 (pt)
CN (1) CN107074912B (pt)
AU (1) AU2015286723B2 (pt)
BR (1) BR112016030577A8 (pt)
CA (1) CA2953451C (pt)
CL (1) CL2017000064A1 (pt)
EA (1) EA035375B1 (pt)
MX (1) MX2017000395A (pt)
MY (1) MY182440A (pt)
PE (1) PE20170291A1 (pt)
PH (1) PH12016502468B1 (pt)
SG (1) SG11201610456UA (pt)
WO (1) WO2016005482A1 (pt)
ZA (1) ZA201700165B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
MY170927A (en) 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
SG11201509663PA (en) 2013-05-30 2015-12-30 Crucell Holland Bv Influenza virus vaccines and uses thereof
EP3587442A1 (en) 2014-07-10 2020-01-01 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2016118937A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
IL265121B2 (en) 2016-09-02 2023-11-01 Us Health Stable group 2 trimers from the stem region of influenza hemagglutinin and their uses
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CN107765001B (zh) * 2017-10-24 2020-03-27 中国科学院苏州纳米技术与纳米仿生研究所 禽流感病毒感染或禽流感疫苗免疫分型试剂盒
PT3743106T (pt) 2018-01-23 2022-08-24 Janssen Vaccines & Prevention Bv Vacinas contra o vírus da influenza e suas utilizações
EP3774884B1 (en) * 2018-03-28 2023-12-06 Sanofi Pasteur Inc. Methods of generating broadly protective vaccine compositions comprising hemagglutinin
CN109239355B (zh) * 2018-09-05 2020-08-25 中牧实业股份有限公司 禽流感病毒h9亚型抗体酶联免疫检测试剂盒
US20210353738A1 (en) * 2018-09-21 2021-11-18 Nutech Ventures Methods of making and using universal centralized influenza vaccine genes
US20230250135A1 (en) * 2019-09-05 2023-08-10 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
GB202004825D0 (en) * 2020-04-01 2020-05-13 Diosynvax Ltd Influenza vaccines
JP2023539771A (ja) * 2020-09-07 2023-09-19 インターベット インターナショナル ベー． フェー． Ｈａ抗体陽性ターゲットのためのｈａステムワクチン
TW202317600A (zh) * 2021-06-23 2023-05-01 潤惠生技股份有限公司 預防多種病毒感染的多價疫苗
WO2023154821A2 (en) * 2022-02-11 2023-08-17 University Of Washington Compositions comprising influenza hemagglutinin stem and method for enhancing cross-protective immunity
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY170607A (en) 2006-09-07 2019-08-20 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
MX2011011331A (es) 2009-05-11 2011-11-18 Crucell Holland Bv Moleculas de union humanas capaces de neutralizar el virus de la influenza h3n2 y usos de las mismas.
CN102939103A (zh) * 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US8900585B2 (en) * 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
DK2731967T3 (en) 2011-07-14 2017-01-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS
MY170927A (en) * 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
SG11201509663PA (en) * 2013-05-30 2015-12-30 Crucell Holland Bv Influenza virus vaccines and uses thereof
EP3587442A1 (en) 2014-07-10 2020-01-01 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof

Also Published As

Publication number Publication date
KR102463632B1 (ko) 2022-11-03
PE20170291A1 (es) 2017-03-26
CN107074912A (zh) 2017-08-18
US10117925B2 (en) 2018-11-06
SG11201610456UA (en) 2017-01-27
MY182440A (en) 2021-01-25
CL2017000064A1 (es) 2017-11-10
AU2015286723B2 (en) 2019-11-21
ZA201700165B (en) 2019-06-26
JP2017521073A (ja) 2017-08-03
US20170189519A1 (en) 2017-07-06
EP3166963B1 (en) 2020-04-22
PH12016502468A1 (en) 2017-04-10
CA2953451C (en) 2023-09-19
BR112016030577A8 (pt) 2021-07-20
JP7094103B2 (ja) 2022-07-01
CA2953451A1 (en) 2016-01-14
KR20170027846A (ko) 2017-03-10
AU2015286723A1 (en) 2017-01-12
MX2017000395A (es) 2018-02-08
EA201692467A1 (ru) 2017-05-31
WO2016005482A1 (en) 2016-01-14
PH12016502468B1 (en) 2017-04-10
EA035375B1 (ru) 2020-06-03
EP3166963A1 (en) 2017-05-17
CN107074912B (zh) 2021-10-29

Similar Documents

Publication Publication Date Title
BR112016030577A2 (pt) vacinas contra o vírus da gripe e usos das mesmas
BR112017000257A2 (pt) vacinas contra o vírus da gripe e usos das mesmas
SV2018005610A (es) Derivados de oxopiridina sustituidos
BR112015014482A2 (pt) vacinas para vírus influenza e seus usos
DK3559022T3 (da) Virulenssvækket bakteriebaseret proteinlevering
CL2016002123A1 (es) Nuevo polisacárido y usos del mismo
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
BR112016030787A2 (pt) entidade química, composição farmacêutica e seu uso
DK3121175T3 (da) 1,3-benzodioxolderivater som ezh1- og/eller ezh2-hæmmere
UY36021A (es) Proteìnas fc multimèricas
BR112016022062A2 (pt) Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112015025748A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna
BR112016030284A2 (pt) Formulações, seu uso ou produção de detergentes de lavagem de louça e sua produção
BR112016026552A2 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
BR112016019868A2 (pt) proteínas de fusão tatk-cdkl5, composições, formulações, e seu uso
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
BR112017011685A2 (pt) composições compreendendo 15-hepe e métodos de tratamento ou prevenção da fibrose usando as mesmas
BR112018004267A2 (pt) concentrado líquido para conservar cosméticos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]